Cardiol Accounts Payable from 2010 to 2025
| CRDL Stock | USD 1.13 0.02 1.74% |
Accounts Payable | First Reported 2010-12-31 | Previous Quarter 8.8 M | Current Value 9.2 M | Quarterly Volatility 3.6 M |
Check Cardiol Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardiol Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 2.6 M, Interest Income of 2.6 M or Depreciation And Amortization of 182.4 K, as well as many indicators such as Price To Sales Ratio of 1 K, Dividend Yield of 0.0 or PTB Ratio of 2.74. Cardiol financial statements analysis is a perfect complement when working with Cardiol Therapeutics Valuation or Volatility modules.
Cardiol | Accounts Payable |
Latest Cardiol Therapeutics' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Cardiol Therapeutics Class over the last few years. An accounting item on the balance sheet that represents Cardiol Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Cardiol Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Cardiol Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardiol Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Cardiol Accounts Payable Regression Statistics
| Arithmetic Mean | 2,748,561 | |
| Geometric Mean | 821,544 | |
| Coefficient Of Variation | 130.86 | |
| Mean Deviation | 3,043,455 | |
| Median | 561,287 | |
| Standard Deviation | 3,596,813 | |
| Sample Variance | 12.9T | |
| Range | 9M | |
| R-Value | 0.86 | |
| Mean Square Error | 3.6T | |
| R-Squared | 0.74 | |
| Significance | 0.00002 | |
| Slope | 649,208 | |
| Total Sum of Squares | 194.1T |
Cardiol Accounts Payable History
About Cardiol Therapeutics Financial Statements
Cardiol Therapeutics investors utilize fundamental indicators, such as Accounts Payable, to predict how Cardiol Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 8.8 M | 9.2 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Cardiol Therapeutics Correlation against competitors. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.